评估第一次和第二次接种 COVID-19 疫苗（牛津大学-阿斯利康公司）后血清中的 CCL2、CCL3 和 IL-29 水平

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS ACS Applied Bio Materials Pub Date : 2024-01-28 DOI:10.1016/j.imbio.2024.152789

Zahra Bagheri-Hosseinabadi , Ayat Kaeidi , Mahdi Rezvani , Gholamhossein Taghipour Khaje Sharifi , Mitra Abbasifard

{"title":"评估第一次和第二次接种 COVID-19 疫苗（牛津大学-阿斯利康公司）后血清中的 CCL2、CCL3 和 IL-29 水平","authors":"Zahra Bagheri-Hosseinabadi , Ayat Kaeidi , Mahdi Rezvani , Gholamhossein Taghipour Khaje Sharifi , Mitra Abbasifard","doi":"10.1016/j.imbio.2024.152789","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Previous studies show that chemokines and cytokines play a very important role in eliciting an appropriate response against viruses. Vaccination causes inflammation in the person receiving the vaccine, accompanied with production of inflammatory molecules by immune cells. The more and better the production and expression of chemokines and cytokines by immune cells, the better the response of the acquired immune system. Chemokines and cytokines are critical in promoting the innate immune response against the COVID-19. Here we intended to assess serum levels of CCL2, CCL3, and interleukin (IL)-29 in patients received COVID-19 vaccine.</p></div><div><h3>Methods</h3><p>In this study, 40 subjects vaccinated with the Oxford–AstraZeneca COVID-19 vaccine were selected. Blood samples were collected before injection of the vaccine, 3–5 days after the first dose injection, and 3–5 days subsequent to the second vaccination. To check the serum level of CCL2, CCL3, and IL-29, ELISA technique was used.</p></div><div><h3>Results</h3><p>Our results indicated that the serum levels of CCL2, CCL3, and IL-29 were significantly higher after first and second dose of vaccination compared to before vaccine administration. Furthermore, serum levels of all these mediators were higher after second dose of vaccine compared to the first vaccine administration.</p></div><div><h3>Conclusions</h3><p>Oxford–AstraZeneca COVID-19 vaccine is able to induce inflammatory CCL2 and CCL3 chemokines as well as protective interferon lambda (IL-29).</p></div>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S017129852400007X/pdfft?md5=48cdf5d1950de614021469356fe3ada8&pid=1-s2.0-S017129852400007X-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Evaluation of the serum levels of CCL2, CCL3, and IL-29 after first and second administrations of the COVID-19 vaccine (Oxford–AstraZeneca)\",\"authors\":\"Zahra Bagheri-Hosseinabadi , Ayat Kaeidi , Mahdi Rezvani , Gholamhossein Taghipour Khaje Sharifi , Mitra Abbasifard\",\"doi\":\"10.1016/j.imbio.2024.152789\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Previous studies show that chemokines and cytokines play a very important role in eliciting an appropriate response against viruses. Vaccination causes inflammation in the person receiving the vaccine, accompanied with production of inflammatory molecules by immune cells. The more and better the production and expression of chemokines and cytokines by immune cells, the better the response of the acquired immune system. Chemokines and cytokines are critical in promoting the innate immune response against the COVID-19. Here we intended to assess serum levels of CCL2, CCL3, and interleukin (IL)-29 in patients received COVID-19 vaccine.</p></div><div><h3>Methods</h3><p>In this study, 40 subjects vaccinated with the Oxford–AstraZeneca COVID-19 vaccine were selected. Blood samples were collected before injection of the vaccine, 3–5 days after the first dose injection, and 3–5 days subsequent to the second vaccination. To check the serum level of CCL2, CCL3, and IL-29, ELISA technique was used.</p></div><div><h3>Results</h3><p>Our results indicated that the serum levels of CCL2, CCL3, and IL-29 were significantly higher after first and second dose of vaccination compared to before vaccine administration. Furthermore, serum levels of all these mediators were higher after second dose of vaccine compared to the first vaccine administration.</p></div><div><h3>Conclusions</h3><p>Oxford–AstraZeneca COVID-19 vaccine is able to induce inflammatory CCL2 and CCL3 chemokines as well as protective interferon lambda (IL-29).</p></div>\",\"PeriodicalId\":2,\"journal\":{\"name\":\"ACS Applied Bio Materials\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2024-01-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S017129852400007X/pdfft?md5=48cdf5d1950de614021469356fe3ada8&pid=1-s2.0-S017129852400007X-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Applied Bio Materials\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S017129852400007X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MATERIALS SCIENCE, BIOMATERIALS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S017129852400007X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

摘要

背景以前的研究表明，趋化因子和细胞因子在引起适当的抗病毒反应中起着非常重要的作用。接种疫苗会导致接种者出现炎症，同时免疫细胞也会产生炎症分子。免疫细胞产生和表达的趋化因子和细胞因子越多越好，后天免疫系统的反应就越好。趋化因子和细胞因子对促进针对 COVID-19 的先天性免疫反应至关重要。在此，我们打算评估接种 COVID-19 疫苗的患者血清中 CCL2、CCL3 和白细胞介素 (IL)-29 的水平。在注射疫苗前、注射第一剂疫苗后 3-5 天和注射第二剂疫苗后 3-5 天采集血样。结果表明，与接种疫苗前相比，接种第一剂和第二剂疫苗后血清中的 CCL2、CCL3 和 IL-29 水平明显升高。结论Oxford-AstraZeneca COVID-19 疫苗能够诱导炎性 CCL2 和 CCL3 趋化因子以及保护性λ干扰素（IL-29）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Evaluation of the serum levels of CCL2, CCL3, and IL-29 after first and second administrations of the COVID-19 vaccine (Oxford–AstraZeneca)

Background

Previous studies show that chemokines and cytokines play a very important role in eliciting an appropriate response against viruses. Vaccination causes inflammation in the person receiving the vaccine, accompanied with production of inflammatory molecules by immune cells. The more and better the production and expression of chemokines and cytokines by immune cells, the better the response of the acquired immune system. Chemokines and cytokines are critical in promoting the innate immune response against the COVID-19. Here we intended to assess serum levels of CCL2, CCL3, and interleukin (IL)-29 in patients received COVID-19 vaccine.

Methods

In this study, 40 subjects vaccinated with the Oxford–AstraZeneca COVID-19 vaccine were selected. Blood samples were collected before injection of the vaccine, 3–5 days after the first dose injection, and 3–5 days subsequent to the second vaccination. To check the serum level of CCL2, CCL3, and IL-29, ELISA technique was used.

Results

Our results indicated that the serum levels of CCL2, CCL3, and IL-29 were significantly higher after first and second dose of vaccination compared to before vaccine administration. Furthermore, serum levels of all these mediators were higher after second dose of vaccine compared to the first vaccine administration.